AR033024A1 - Conjugados de pregabalina-lactosa - Google Patents

Conjugados de pregabalina-lactosa

Info

Publication number
AR033024A1
AR033024A1 ARP020101140A ARP020101140A AR033024A1 AR 033024 A1 AR033024 A1 AR 033024A1 AR P020101140 A ARP020101140 A AR P020101140A AR P020101140 A ARP020101140 A AR P020101140A AR 033024 A1 AR033024 A1 AR 033024A1
Authority
AR
Argentina
Prior art keywords
disorders
lactose
pregabaline
pregabalin
diseases
Prior art date
Application number
ARP020101140A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR033024A1 publication Critical patent/AR033024A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

De acuerdo con la presente invencion, se proporciona compuestos conjugados de pregabalina-lactosa. También se proporciona como parte de la presente invencion un nuevo método para tratar en un sujeto trastornos o enfermedades del sistema nervioso central, que incluyen trastornos de crisis convulsivas, dolor, depresion, ansiedad, trastornos de sueno, trastornos consuntivos, psicosis, discinesia tardía, enfermedades de Huntington o Parkinson, administrando al sujeto una cantidad farmacéuticamente eficaz de un conjunto de pregabalina-lactosa.
ARP020101140A 2001-03-30 2002-03-27 Conjugados de pregabalina-lactosa AR033024A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28017601P 2001-03-30 2001-03-30

Publications (1)

Publication Number Publication Date
AR033024A1 true AR033024A1 (es) 2003-12-03

Family

ID=23072002

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101140A AR033024A1 (es) 2001-03-30 2002-03-27 Conjugados de pregabalina-lactosa

Country Status (32)

Country Link
US (1) US7022678B2 (es)
EP (1) EP1377318A2 (es)
JP (1) JP2004524357A (es)
KR (1) KR20040008146A (es)
CN (1) CN1511043A (es)
AP (1) AP2003002873A0 (es)
AR (1) AR033024A1 (es)
BG (1) BG108193A (es)
BR (1) BR0208439A (es)
CA (1) CA2440468C (es)
CZ (1) CZ20032547A3 (es)
DO (1) DOP2002000356A (es)
EA (1) EA200300954A1 (es)
EC (1) ECSP034740A (es)
EE (1) EE200300480A (es)
GT (1) GT200200051A (es)
HU (1) HUP0303956A2 (es)
IL (1) IL157879A0 (es)
IS (1) IS6912A (es)
MA (1) MA27004A1 (es)
MX (1) MXPA03007437A (es)
NO (1) NO20034348L (es)
OA (1) OA12456A (es)
PA (1) PA8542101A1 (es)
PE (1) PE20021016A1 (es)
PL (1) PL369179A1 (es)
SK (1) SK11832003A3 (es)
SV (1) SV2003000928A (es)
TN (1) TNSN02038A1 (es)
UY (1) UY27233A1 (es)
WO (1) WO2002078747A2 (es)
ZA (1) ZA200306608B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9710536A (pt) 1996-07-24 1999-08-17 Warner Lambert Co Isobutilgaba e seus derivados para o tratamento da dor
KR20080034205A (ko) * 2005-09-19 2008-04-18 테바 파마슈티컬 인더스트리즈 리미티드 (ｓ)-프레가발린의 신규한 합성을 위한 주요 중간체인 키랄3-카르바모일메틸-5-메틸 헥산산
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP2297090A1 (en) * 2008-06-23 2011-03-23 Teva Pharmaceutical Industries Ltd. Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
WO2010115612A2 (en) 2009-04-10 2010-10-14 Synthon B.V. Pregabalin compositions
WO2010150221A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Taste masked pharmaceutical compositions of pregabalin
HU230031B1 (hu) * 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
CN103494796B (zh) * 2013-09-30 2016-01-20 浙江华义医药有限公司 普瑞巴林稳定的药物组合物及其制备方法
CN104311608B (zh) * 2014-10-28 2016-10-05 河南中烟工业有限责任公司 亲水型烟草增香保润剂Mal-Hyp、制备方法及其应用
CN104370986B (zh) * 2014-10-28 2017-07-04 河南中烟工业有限责任公司 糖衍生物烟用增香保润剂Mal‑Pro、制备方法及其应用
CN105434395B (zh) * 2015-12-31 2018-12-11 常州市阳光药业有限公司 普瑞巴林胶囊及其制备方法
CN105520918B (zh) * 2015-12-31 2018-12-11 常州市阳光药业有限公司 普瑞巴林胶囊

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
FR2781793B1 (fr) * 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
AU762599B2 (en) * 1998-10-16 2003-06-26 Warner-Lambert Company Method for the treatment of mania and bipolar disorder
JP2004514699A (ja) * 2000-11-30 2004-05-20 ファイザー・プロダクツ・インク Ｇａｂａアゴニストおよびソルビトールデヒドロゲナーゼ阻害剤の組合せ

Also Published As

Publication number Publication date
PE20021016A1 (es) 2002-11-14
MXPA03007437A (es) 2003-11-18
IL157879A0 (en) 2004-03-28
SK11832003A3 (sk) 2004-04-06
WO2002078747A2 (en) 2002-10-10
UY27233A1 (es) 2002-10-31
EE200300480A (et) 2003-12-15
EP1377318A2 (en) 2004-01-07
CA2440468C (en) 2008-09-02
EA200300954A1 (ru) 2004-02-26
WO2002078747A3 (en) 2003-10-09
WO2002078747A8 (en) 2003-12-04
WO2002078747A9 (en) 2003-12-31
ZA200306608B (en) 2004-11-25
HUP0303956A2 (hu) 2004-04-28
US7022678B2 (en) 2006-04-04
CN1511043A (zh) 2004-07-07
US20020187941A1 (en) 2002-12-12
JP2004524357A (ja) 2004-08-12
PL369179A1 (en) 2005-04-18
ECSP034740A (es) 2003-12-24
PA8542101A1 (es) 2002-10-28
AP2003002873A0 (en) 2003-09-30
BG108193A (en) 2004-09-30
MA27004A1 (fr) 2004-12-20
OA12456A (en) 2004-08-24
NO20034348D0 (no) 2003-09-29
TNSN02038A1 (fr) 2005-12-23
CA2440468A1 (en) 2002-10-10
KR20040008146A (ko) 2004-01-28
BR0208439A (pt) 2004-03-23
DOP2002000356A (es) 2002-12-15
CZ20032547A3 (en) 2004-04-14
SV2003000928A (es) 2003-07-29
NO20034348L (no) 2003-09-29
GT200200051A (es) 2002-11-15
IS6912A (is) 2003-08-14

Similar Documents

Publication Publication Date Title
AR033024A1 (es) Conjugados de pregabalina-lactosa
BRPI0408026A (pt) Quinazolinas úteis como moduladores de canais de ìon
HN2001000037A (es) Derivados de eteres de pirazol como agentes antiinflamatorios/analgesicos
AR041725A1 (es) Prevencion, tratamiento de la enfermedad sinucleinopatica y composicion farmacologica
BR0316438A (pt) Uso de eritropoietina em doenças cardìacas
BE2012C040I2 (es)
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
HK1102991A1 (en) Pharmaceutical formulation of decitabine
ATE463247T1 (de) Bupropion metaboliten zur behandlung von angstzuständen
GT200500086A (es) Bioconversion estereoselectiva de dinitrilos alifaticos en acidos cianocarboxilicos.
BR0212611A (pt) Compostos de pirazolila substituìdos para o tratamento da inflamação
HK1125291A1 (en) Method of using guava extract and composition including guava extract
CO5370677A1 (es) Nuevos derivados heterociclicos de carbonil sustituido y su uso como ligantes receptores d3 de dopamina
UY27759A1 (es) Combinaciones de medicamentos que contienen compuestos heterocíclicos y un nuevo agente anticolinérgico.
BRPI0407693A (pt) uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos
BRPI0409380A (pt) composições farmacêuticas
AU2003277280A1 (en) Biphenyls and fluorenes as imaging agents in alzheimer's disease
BR0011996A (pt) Preparação de piperidin-4-onas substituìdas
CR7060A (es) Conjugados de pregabalina-lactosa
BR0009194A (pt) Composição do resorcinol
SV2002000458A (es) Derivados de sulfonamida ref. x-13113
BRPI0513395A (pt) uso de um esteróide para aumentar a permeabilidade cutánea
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária
HN2000000090A (es) Sal difosfato de un derivado de 4sustituido-9-desoxo-9a-aza-9a-homoeritromicina y su composicion farmaceutica.
BRPI0416202A (pt) formulações inibidoras de fosfodiesterase v

Legal Events

Date Code Title Description
FB Suspension of granting procedure